{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.7","upperLimit":"59.1","value":"48.4"},{"groupId":"OG001","lowerLimit":"20.8","upperLimit":"40.6","value":"30.0"},{"groupId":"OG002","lowerLimit":"33.3","upperLimit":"54.7","value":"43.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"89"}],"units":"Participants"}],"description":"MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \\>0 to 35% Ph + metaphases.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"ITT Cytogenetic Population included all participants who were randomized and had a cytogenetic assessment at Baseline with ≥20 metaphases examined, regardless of whether they received the assigned study drug. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"12 months after the first dose of study treatment","title":"Percentage of Participants With Major Cytogenetic Response (MCyR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}